4,719 Shares in Hims & Hers Health, Inc. (NYSE:HIMS) Acquired by Rakuten Securities Inc.

Rakuten Securities Inc. purchased a new stake in Hims & Hers Health, Inc. (NYSE:HIMS) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 4,719 shares of the company’s stock, valued at approximately $114,000.

Other institutional investors have also modified their holdings of the company. State Street Corp raised its stake in shares of Hims & Hers Health by 4.7% in the third quarter. State Street Corp now owns 4,626,543 shares of the company’s stock valued at $85,221,000 after acquiring an additional 206,078 shares in the last quarter. Geode Capital Management LLC increased its holdings in Hims & Hers Health by 12.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock worth $79,029,000 after purchasing an additional 482,177 shares during the period. Wellington Management Group LLP raised its position in Hims & Hers Health by 34.5% in the 3rd quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock valued at $63,446,000 after purchasing an additional 883,230 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Hims & Hers Health by 7.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,796,838 shares of the company’s stock valued at $43,448,000 after buying an additional 129,416 shares during the period. Finally, Yong Rong HK Asset Management Ltd acquired a new position in shares of Hims & Hers Health during the fourth quarter worth about $41,104,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Trading Down 2.0 %

HIMS stock opened at $34.00 on Thursday. Hims & Hers Health, Inc. has a twelve month low of $11.20 and a twelve month high of $72.98. The company has a market capitalization of $7.55 billion, a P/E ratio of 77.27 and a beta of 1.37. The business has a 50 day simple moving average of $38.23 and a 200-day simple moving average of $27.90.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. Research analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently weighed in on HIMS shares. BTIG Research began coverage on shares of Hims & Hers Health in a report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 target price on the stock. Truist Financial raised their price objective on shares of Hims & Hers Health from $24.00 to $39.00 and gave the company a “hold” rating in a report on Wednesday, February 26th. Morgan Stanley downgraded shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and boosted their target price for the stock from $42.00 to $60.00 in a research note on Tuesday, February 18th. TD Cowen reaffirmed a “buy” rating and set a $28.00 price target on shares of Hims & Hers Health in a report on Wednesday, November 20th. Finally, Leerink Partners increased their price objective on Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a report on Tuesday, February 25th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, Hims & Hers Health currently has an average rating of “Hold” and a consensus price target of $37.23.

Insider Buying and Selling

In other news, insider Soleil Boughton sold 4,152 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $60.69, for a total transaction of $251,984.88. Following the completion of the sale, the insider now directly owns 157,345 shares in the company, valued at approximately $9,549,268.05. This trade represents a 2.57 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Andrew Dudum sold 78,127 shares of the company’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $29.62, for a total value of $2,314,121.74. Following the completion of the sale, the chief executive officer now owns 109,956 shares in the company, valued at approximately $3,256,896.72. This represents a 41.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 969,191 shares of company stock valued at $34,005,375 over the last three months. 17.71% of the stock is currently owned by company insiders.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.